The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia

Haematologica

Volumn 99, Issue 11, 2014, Pages 1716-1721

  Tong, Wing H ^a   Pieters, Rob ^a,b   de Groot Kruseman, Hester A ^c   Hop, Wim C J ^d   Boos, Joachim ^e   Tissing, Wim J E ^f   van der Sluis, Inge M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Department of Radiation Oncology   (Netherlands)

^c DCOG Dutch Childhood Oncology Group   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ASPARAGINASE; ASPARAGINASE MACROGOL; CHOLESTEROL; DEXAMETHASONE; ERWINIA ASPARAGINASE; LOW MOLECULAR WEIGHT HEPARIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADVERSE DRUG REACTION; ALLERGY; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; DISEASE ASSOCIATION; DRUG ACTIVITY; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERAMMONEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PANCREATITIS; PROPORTIONAL HAZARDS MODEL; THROMBOSIS; BLOOD; COMPLICATION; DRUG ADMINISTRATION; DYSLIPIDEMIAS; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; HUMANS; INFANT; LIPIDS; MALE; PANCREATITIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THROMBOSIS;

EID: 84908406447     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.109413     Document Type: Article

References (15)

1. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwiniaasparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation forResearch and Treatment of CancerChildren's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-9.
2. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896-904.
3. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive highdose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-42.
4. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-8.
5. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23(28):7161-7.
6. Tong WH, Pieters R, Kaspers GJ, Te Loo DM, Bierings MB, van den Bos C, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2026-33.
7. Lanvers C, Vieira Pinheiro JP, Hempel G, Wuerthwein G, Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of Lasparaginase in human serum. Anal Biochem. 2002;309(1):117-26.
8. Tong WH, Pieters R, van der Sluis IM. Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase. Pediatr Blood Cancer. 2012;58(2):317-8.
9. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli Lasparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--DanaFarber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31(9): 1202-10.
10. Ridola V, Buonuomo PS, Maurizi P, Putzulu R, Annunziata ML, Pietrini D, et al. Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer. 2008;50(2):378-80.
11. Hoogerbrugge N, Jansen H, Hoogerbrugge PM. Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity. Leukemia. 1997;11(8):1377-9.
12. Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer. 1994;74(12):3234-9.
13. Jaing TH, Lin JL, Lin YP, Yang SH, Lin JJ, Hsia SH. Hyperammonemic encephalopathy after induction chemotherapy for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31(12):955-6.
14. Leonard JV, Kay JD. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet. 1986;1(8473): 162-3.
15. Pound CM, Keene DL, Udjus K, Humphreys P, Johnston DL. Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2007;29(3):183-6